Royce & Associates LP Acquires 214,166 Shares of Privia Health Group, Inc. $PRVA

Royce & Associates LP lifted its holdings in shares of Privia Health Group, Inc. (NASDAQ:PRVA) by 54.5% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 607,191 shares of the company’s stock after acquiring an additional 214,166 shares during the quarter. Royce & Associates LP’s holdings in Privia Health Group were worth $15,119,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the stock. Royal Bank of Canada raised its holdings in shares of Privia Health Group by 63.5% during the first quarter. Royal Bank of Canada now owns 245,633 shares of the company’s stock valued at $5,514,000 after purchasing an additional 95,371 shares during the last quarter. AQR Capital Management LLC grew its position in Privia Health Group by 24.7% in the 1st quarter. AQR Capital Management LLC now owns 40,781 shares of the company’s stock worth $916,000 after purchasing an additional 8,068 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Privia Health Group by 3.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 118,764 shares of the company’s stock valued at $2,666,000 after buying an additional 3,714 shares during the last quarter. Intech Investment Management LLC raised its stake in Privia Health Group by 55.1% during the 1st quarter. Intech Investment Management LLC now owns 56,553 shares of the company’s stock valued at $1,270,000 after buying an additional 20,082 shares during the last quarter. Finally, Acadian Asset Management LLC bought a new position in shares of Privia Health Group during the 1st quarter valued at $154,000. Hedge funds and other institutional investors own 94.48% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on the company. Jefferies Financial Group reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Privia Health Group in a report on Thursday. Weiss Ratings restated a “hold (c)” rating on shares of Privia Health Group in a research note on Monday, December 29th. Barclays increased their price objective on shares of Privia Health Group from $22.00 to $23.00 and gave the stock an “equal weight” rating in a research note on Monday, November 10th. Canaccord Genuity Group raised their price objective on shares of Privia Health Group from $34.00 to $35.00 and gave the stock a “buy” rating in a report on Friday. Finally, Truist Financial upped their target price on shares of Privia Health Group from $31.00 to $33.00 and gave the company a “buy” rating in a report on Monday. Thirteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, Privia Health Group presently has a consensus rating of “Moderate Buy” and an average price target of $30.93.

Privia Health Group News Summary

Here are the key news stories impacting Privia Health Group this week:

• Positive Sentiment: Truist raised its price target on PRVA from $31 to $33 and reiterated a “buy” rating — the new target implies roughly ~37% upside from the current price, which can attract buyers and support the rally. Article Title
• Positive Sentiment: Privia announced it will acquire Evolent’s ACO business to expand its value‑based care scale — a strategic deal that could boost managed-care revenue, accelerate margin improvement in value-based contracts, and justify higher multiples if integration succeeds. Privia Health Expands Value Based Care Scale With Evolent ACO Acquisition
• Negative Sentiment: Director Matthew Shawn Morris sold a combined ~24,338 shares across Feb. 26–27 for about $608k; he still holds 68,188 shares. Significant director sales can create short‑term selling pressure or raise governance/sentiment questions for some investors. SEC filing: SEC Form 4
• Negative Sentiment: CFO David Mountcastle sold a combined ~13,058 shares across Feb. 26–27 for roughly $327k; he continues to own 172,909 shares. Insider sales by senior finance executives are often watched closely and can temper enthusiasm from positive catalysts. SEC filing: SEC Form 4

Privia Health Group Trading Up 1.2%

Shares of NASDAQ:PRVA opened at $24.04 on Tuesday. The stock has a 50 day moving average of $23.07 and a 200 day moving average of $23.52. The company has a market cap of $2.96 billion, a PE ratio of 141.41, a price-to-earnings-growth ratio of 1.59 and a beta of 0.83. Privia Health Group, Inc. has a 12-month low of $18.77 and a 12-month high of $26.51.

Privia Health Group (NASDAQ:PRVA) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.21. The business had revenue of $541.17 million for the quarter, compared to the consensus estimate of $516.61 million. Privia Health Group had a net margin of 1.08% and a return on equity of 3.06%. The company’s revenue for the quarter was up 17.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.21 earnings per share. Equities research analysts predict that Privia Health Group, Inc. will post 0.14 earnings per share for the current fiscal year.

Insider Activity at Privia Health Group

In other news, Director Matthew Shawn Morris sold 16,550 shares of the business’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $25.00, for a total value of $413,750.00. Following the transaction, the director owned 68,188 shares of the company’s stock, valued at approximately $1,704,700. The trade was a 19.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO David Mountcastle sold 23,887 shares of the firm’s stock in a transaction on Friday, December 12th. The shares were sold at an average price of $25.03, for a total transaction of $597,891.61. Following the transaction, the chief financial officer directly owned 172,909 shares of the company’s stock, valued at $4,327,912.27. The trade was a 12.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 74,930 shares of company stock valued at $1,874,410 over the last 90 days. 10.70% of the stock is currently owned by corporate insiders.

Privia Health Group Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.